Why Supernus Pharmaceuticals’ Stock is Catching Investors’ Attention
Supernus Pharmaceuticals reported a significant revenue of £174.2 million for Q4, a 6% increase year-on-year, surpassing analyst expectations by 12.2%. The company’s earnings per share reached £0.27, reflecting strong financial performance but accompanied by a cautious 2025 outlook. Supernus has achieved an
